Third-line therapy in advanced non-small cell lung cancer

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Advances in first- and second-line treatments for non-small cell lung cancer (NSCLC) have increased the number of patients requiring third-line therapy.
• Erlotinib is currently the only standard third-line treatment option for advanced NSCLC.

Purpose of the Study:

• To investigate the efficacy and safety of various third-line treatment strategies in advanced non-small cell lung cancer (NSCLC).
• To compare single-agent chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), doublet chemotherapy, and chemo-targeted therapy as third-line treatments.

Main Methods:

• Retrospective review of 233 patients with stage IIIb or IV NSCLC.
• Analysis of survival differences between patients receiving different third-line treatment modalities.

Main Results:

• Median progression-free survival (PFS) was highest with EGFR-TKIs (3.83 months) and chemo-targeted therapy (3.29 months).
• Median overall survival (OS) was significantly longer in the EGFR-TKIs (11.16 months) and chemo-targeted therapy (9.33 months) groups compared to single-agent (8.24 months) and doublet chemotherapy (8.49 months) (p=0.02).
• Higher rates of grade III-IV toxicities were observed with doublet chemotherapy (57.3%) and chemo-targeted therapy (44.0%) compared to EGFR-TKIs (16.4%) and single-agent chemotherapy (27.6%).
• Patients who never smoked, had adenocarcinoma, good ECOG performance status (PS), and achieved disease control after first- and second-line treatments had prolonged OS.

Conclusions:

• Third-line treatment can benefit specific non-small cell lung cancer (NSCLC) patient subgroups, including never-smokers, adenocarcinoma patients, those with good performance status, and those with prior disease control.
• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemo-targeted therapy demonstrate superior overall survival (OS) compared to traditional chemotherapy regimens in the third-line setting.